Thus, we explored the influence of abnormal HAT1 expression on the sensitivity of several commonly used drugs in pancreatic cancer cells, which showed the significantly reduced IC50 for gemcitabine when HAT1 was knocked down, while the sensitivity of other drugs was slightly reduced or unchanged (Fig. 1a). The gene discussed is HAT1; the disease is pancreatic neoplasm.